| |
We invite you to join us at the Fierce Medical Affairs Strategic Summit West. Join medical affairs, field medical, and medical communications teams to share best practices, gain actionable insights and crowdsource ideas to their unique challenges from their peers. Register now
|
|
Today's Big NewsJul 6, 2023 |
| By Fraiser Kansteiner With a full approval in hand, Leqembi has become the first treatment shown to reduce the rate of disease progression and slow cognitive and functional decline in adults with Alzheimer’s disease under the FDA's traditional approval pathway. Now, the companies can start with their ambitious launch plans. |
|
|
|
By Annalee Armstrong Aslan Pharmaceuticals is trying to come for Dupixent’s billion-dollar crown in atopic dermatitis, but with mid-stage data showing a more comparable than superior profile, the company hopes less frequent dosing and lower rates of a known side effect may lure patients onto eblasakimab. |
By Ayla Ellison Last week, I introduced you to the Fierce 50, a groundbreaking project that celebrates the leaders and visionaries igniting change in healthcare delivery, drug development, research and beyond. Today, I’m unveiling the five categories that will shape this special report. |
By Andrea Park Nearly three years in the making, Renalytix has finally reeled in the FDA’s authorization for its prognostic test aimed at predicting an oncoming decline in kidney function. |
|
Wednesday, July 12, 2023 | 2pm ET/11am PT In this webinar, we will explore how critical it is for life sciences companies to use data to analyze the behavior of cancer at the individual level, uncover new targets and biomarkers for precision therapies, and increase the value of existing oncology drugs to new indications. Register now.
|
|
By Zoey Becker It's been almost one year since Congress and the Biden administration passed the Inflation Reduction Act. As the Medicare negotiation measures creep closer, drugmakers such as Genentech are facing the "unintended consequences" of the law, CEO Alexander Hardy said in an interview. |
By Andrea Park Still taking advantage of the fact that competitor Philips’ respiratory care business remains stanched by its ongoing CPAP machine recall, ResMed continues to carve out an even bigger foothold for itself in the shared space. |
By Kevin Dunleavy The price of priority review vouchers is falling. Just ask Sarepta Therapeutics. Since 2017, the company has sold off three PRVs—getting less in return for each successive sale. The most recent sale came Wednesday as Sarepta revealed a $102 million deal for its PRV which came along with the FDA’s endorsement of Duchenne muscular dystrophy treatment Elevidys. |
By Max Bayer Tessa Therapeutics is closing its doors after reportedly failing to secure additional financing or find a buyer. The company had raised more than $200 million since 2017. |
By James Waldron Thermo Fisher Scientific has given a glimpse into how its “disciplined capital deployment strategy” will work in reality, fronting close to a billion dollars to get its hands on real-world data intelligence company CorEvitas. |
By Gabrielle Masson Pfizer is backing Caribou Biosciences with a $25 million equity investment, money the genome editing company will pour into its allogeneic CAR-T cell therapy for multiple myeloma. |
Fierce podcastsDon't miss an episode |
| | This week on "The Top Line," we discuss the American Diabetes Association's annual conference, plus a statement about transgender care, light therapy, and the rest of the week's headlines. |
|
|---|
|
|
|
Wednesday, July 12, 2023 | 11:00am ET / 8:00am PT Join us for this insightful discussion on how to unlock the full potential of liquid biopsy and be an integral part of the future of precision medicine. We’ll take a deep dive into the latest strategies and solutions designed to help overcome current challenges and empower researchers and clinicians with enhanced capabilities. Register now.
|
|
| ResearchThe right sourcing strategy can help save of millions of dollars—learn about developing a strategy for sourcing the cGMP chemicals critical to your processes. Sponsored by: Thermo Fisher Scientific Production Chemicals and Services |
| WhitepaperLearn how a GPCR-focused library with a cell-based biopanning strategy led to the discovery of 13 high-affinity and selective anti-GLP-1R antibodies with highly developable therapeutic properties. Sponsored by: Twist Bioscience |
| eBookThis eBook identifies the trends driving major change in the Medical Affairs (MA) function. It also outlines the strategic and tactical implications for MA leaders and team members. Sponsored by: Blue Matter, strategic consultants in the life sciences |
| eBookTake a look at the reporting tools sponsors need to access insights earlier in the clinical trial enrollment funnel, so you can take informed actions. Sponsored by: OneStudyTeam |
| WhitepaperLearn how to develop a high-performing supply chain for cGMP chemicals used throughout your bioprocessing workflows. Sponsored by: Thermo Fisher Scientific Production Chemicals and Services |
| WhitepaperExplore how clinical supply can be scaled up as decentralized programs progress, and how technological solutions can accelerate trial deployment. Sponsored by: Catalent Clinical Supply |
| WhitepaperLearn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region. Sponsored by: Catalent |
| |
|
